Levosimendan Altan

Levosimendan, the active ingredient in Levosimendan Altan, is a calcium sensitizer/inodilator presented as an intravenous solution for intravenous use. It improves cardiac contractility in patients with acute decompensated heart failure.

GNH USA supplies Levosimendan Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is employed in the management of heart‑failure related conditions where enhanced cardiac output is required.

Acute decompensated heart failure: improves hemodynamics and reduces symptoms of congestion. Low cardiac output syndrome (post‑cardiac surgery): supports myocardial performance and systemic perfusion. Cardiogenic shock (adjunct therapy): may augment cardiac output when conventional measures are insufficient.

Levosimendan may be associated with several adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache - Hypotension - Nausea - Flushing - Tachycardia - Arrhythmia

Serious or Rare Side Effects: - Severe hypotension leading to syncope - Ventricular arrhythmias - Myocardial ischemia - Anaphylactic or severe allergic reactions - Elevated liver enzymes - Acute renal failure

When using Levosimendan, clinicians should consider several safety measures.

Monitor blood pressure: avoid excessive hypotension. Assess cardiac rhythm: watch for new or worsening arrhythmias. Evaluate renal and hepatic function: adjust use in impairment. Avoid concurrent strong vasodilators: may potentiate hypotensive effects. Pregnancy and lactation: use only if benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other potent vasodilators (e.g., nitroglycerin) may cause severe hypotension. - Strong CYP450 inhibitors (e.g., ketoconazole) can increase plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired increase in cardiac output. - Diuretics: may exacerbate electrolyte disturbances. - Anticoagulants: monitor for bleeding if hypotension occurs.